Association of Sirolimus Use With Risk for Skin Cancer in a Mixed-Organ Cohort of Solid-Organ Transplant Recipients With a History of Cancer | Zendy

Pritesh S. Karia | Zendy; Jamil Azzi | Zendy; Eliot Heher | Zendy; Victoria M. Hills | Zendy; Chrysalyne D. Schmults | Zendy

Open Access

Association of Sirolimus Use With Risk for Skin Cancer in a Mixed-Organ Cohort of Solid-Organ Transplant Recipients With a History of Cancer

Author(s) -

Pritesh S. Karia,

Jamil Azzi,

Eliot Heher,

Victoria M. Hills,

Chrysalyne D. Schmults

Publication year - 2016

Publication title -

jama dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.128

H-Index - 166

eISSN - 2168-6084

pISSN - 2168-6068

DOI - 10.1001/jamadermatol.2015.5548

Subject(s) - medicine , sirolimus , organ transplantation , cancer , skin cancer , cohort , solid organ , oncology , transplantation

Solid-organ transplant recipients (OTRs) are at an increased risk for skin cancer. Prior studies have demonstrated a reduced incidence of skin cancer in renal OTRs treated with sirolimus. However, little information exists on the use of sirolimus for the prevention of skin cancer in nonrenal OTRs or those already diagnosed as having a posttransplant cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research